Accéder au contenu
Merck
Toutes les photos(1)

Documents

1180503

USP

Dextromethorphan

United States Pharmacopeia (USP) Reference Standard

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H25NO
Numéro CAS:
125-71-3
Poids moléculaire :
271.40
Numéro CE :
204-752-2
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

dextromethorphan

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1

Clé InChI

MKXZASYAUGDDCJ-NJAFHUGGSA-N

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dextromethorphan USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

PHR1018

Dextromethorphan HBr, certified reference material, pharmaceutical secondary standard

1181007

Dextromethorphan hydrobromide, United States Pharmacopeia (USP) Reference Standard

D0740000

Dextromethorphan hydrobromide, European Pharmacopoeia (EP) Reference Standard

Y0000261

Dextromethorphan impurity A, European Pharmacopoeia (EP) Reference Standard

1181040

Dextromethorphan Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR2206

Dextromethorphan N-Oxide HCl, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1976

Dextromethorphan Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbonesEnvironment
GHS06,GHS09

Mention d'avertissement

Danger

Mentions de danger

H301,H411

Classification des risques

Acute Tox. 3 Oral - Aquatic Chronic 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 7

1 of 7

4-(Butylamino)benzoic acid 97%

Sigma-Aldrich

262412

4-(Butylamino)benzoic acid

Dextrorphan tartrate powder

Sigma-Aldrich

D127

Dextrorphan tartrate

Docusate sodium United States Pharmacopeia (USP) Reference Standard

USP

1224802

Docusate sodium

Dextrorphan tartrate Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1974

Dextrorphan tartrate

Flumazenil >99% (HPLC), solid

Sigma-Aldrich

F6300

Flumazenil

Tolbutamide analytical standard

Supelco

T0891

Tolbutamide

Phenacetin ≥98.0% (HPLC)

Sigma-Aldrich

77440

Phenacetin

Eric Guenin et al.
Clinical drug investigation, 34(9), 609-616 (2014-07-17)
Dextromethorphan hydrobromide (DM) is a widely used antitussive. This study determined, for the first time, the basic pharmacokinetic profile of DM and its active metabolite, dextrorphan (DP) in children and adolescents. Thirty-eight male and female subjects at risk for developing
Rüdiger Kaspera et al.
Biochemical pharmacology, 91(1), 109-118 (2014-06-29)
Ritonavir, an HIV protease inhibitor, is successfully used for the prevention and treatment of HIV infections. Ritonavir pharmacokinetics are complicated by inhibition, induction and pharmacogenetics of cytochrome P450 (CYP) enzymes mediating its clearance. This investigation revealed that CYP2J2, along with
Sang Yoon Lee et al.
Xenobiotica; the fate of foreign compounds in biological systems, 45(2), 131-138 (2014-08-26)
1. The herb-drug interaction potential of Hwang-Ryun-Hae-Dok-Tang (HR) extracts mediated by cytochrome P450 (CYP) inhibition was determined using human liver microsomes. 2. HR strongly inhibited CYP1A2 and moderately inhibited CYP2C19, CYP2D6, and CYP3A4 (testosterone) but not CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP3A4
Yuka Muroi et al.
Drug metabolism and pharmacokinetics, 29(5), 360-366 (2014-03-22)
Genetic variations in cytochrome P450 2D6 (CYP2D6) contribute to interindividual variability in the metabolism of clinically used drugs, e.g., tamoxifen. CYP2D6 is genetically polymorphic and is associated with large interindividual variations in therapeutic efficacy and drug toxicity. In this study
Véronique Morel et al.
Fundamental & clinical pharmacology, 28(6), 671-680 (2014-04-08)
N-methyl-D-aspartate receptor (NMDAR) antagonists may be given in persistent neuropathic pain, but adverse events especially with ketamine may limit their clinical use. Less central and cognitive adverse events are described with dextromethorphan and memantine. These molecules have been explored in
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique